Drug Trial Radar · NCT03963232
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
Last checked: Nov 20, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
520
Actual
Start
Jul 30, 2019
Primary completion
Jul 27, 2021
Study completion Mar 11, 2022
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
Conditions
- Episodic Migraine
Interventions
GalcanezumabDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase.Time frame: Baseline, 3 Months
Locations
40 sites in 3 countries. Site status is shown where the registry gives one.
Xuanwu Hospital-Capital Medical University
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital Chongqing Medical University
Chongqing, Chongqing Municipality, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
The Affiliated Hospital of Guiyang Medical College
Guiyang, Guizhou, China
The First Affiliated Hospital of Zhengzhou Universtiy
Zhengzhou, Henan, China
Wuhan Union Hospital
Wuhan, Hubei, China
Tongji Hosp Tongji Med Col Huazhong Univ of Sci & Tech
Wuhan, Hubei, China
Xiangya Hospital, Central South University
Changsha, Hunan, China
The First Affliated Hospital of Soochow University
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
No.2 Hospital Affiliated to Jilin University
Changchun, Jilin, China
Tianjin Huanhu Hospital
Tianjin, Jinnan District, China
Jiangsu Province Hospital
Nanjing, Nanjing, China
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Jinan Central Hospital
Jinan, Shandong, China
People's hospital of Rizhao
Rizhao, Shandong, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
HuaShan Hospital Affiliated To Fudan University
Shanghai, Shanghai Municipality, China
West China Hospital Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Zhejiang Hospital
Hangzhou, Zhejiang, China
Bao Tou Central Hospital
Baotou, Zizhiqu, China
Gobind Ballabh Pant Hospital
New Delhi, India
Apollo Hospitals International Ltd.
Ahmedabad, Gujarat, India
Artemis Hospital
Gurgaon, Haryana, India
Mangala Hospitals & Mangala Kidney Foundation
Mangalore, Karnataka, India
CHL - Apollo Hospital
Indore, Madh Prad, India
Getwell Hospital & Research Institute
Nagpur, Maharashtra, India
HCG Manavata Cancer Centre
Nashik, Maharashtra, India
Deenanath Mangeshkar Hospital & Research Centre
Pune, Maharashtra, India
All India Institute of Medical Sciences
New Delhi, National Capital Territory of Delhi, India
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, India
First Moscow State Medical University n.a. Sechenov
Moscow, Russia
University Headache Clinic
Moscow, Russia
OOO "Medis"
Nizhny Novgorod, Russia
Academician I.P. Pavlov First St-Petersburg State Medical University
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.